Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of prehydration on low-dose cisplatin pharmacokinetics
NL-OMON42571Phase 4Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisplatin in cancer and Non-hematologic malignancy (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Difference in cisplatin pharmacokinetics. Started Jan 2019; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
cancerNon-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON42571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42571.